BERLIN (Reuters) - Germany has requested around 5% of the supply of remdesivir under a six-month European Union supply deal, its health ministry said on Monday, despite criticism of the deal due to a lack of evidence about the antiviral drug’s effectiveness in treating COVID-19.
Berlin has requested 155,000 vials of remdesivir under the EU’s six-month deal to buy up to 3 million vials from U.S. drug maker Gilead, the ministry said in a statement.
A course of treatment for COVID-19 requires six doses and costs 2,070 euros (1,866 pounds) per treatment, under the terms of the deal.
Medical experts have called on Brussels to renegotiate the 1 billion euro contract signed with Gilead last month after remdesivir showed poor results in a large trial conducted by the World Health Organization.
Reporting by Douglas Busvine; Editing by Susan Fenton
Our Standards: The Thomson Reuters Trust Principles.